The Colon Club

KElizabeth wrote:

NHMike wrote:Do you know your KRAS mutation?

Yes. I have KRAS mutation as well as TP53 and APC.

I think that you're the first person that I've run into here with multiple mutations and these are in multiple genes as well.

TP53 and APC are supposed to regulate cell growth and prevent tumors.

I hope that your doctors can come up with something.

Hi KElizabeth,

Sorry to know the clinical trial did not work for you.

Last week I had a conversion with my Onc. In his opinion, Roche's immunotherapy for mCRC is a good candidate for a clinical trial. Please see Roche's Investor Update dated May 18, 2017.
It states that if RO6958688 is combined with atezolizumab, the disease control is 82%:
18% partial response
64% stable disease
https://www.roche.com/investors/updates ... -05-18.htm

Currently Roche have phase 1 trials for there medicine in the US:
https://clinicaltrials.gov/ct2/show/NCT ... =ab&rank=1

boswind wrote:Hi KElizabeth,

Sorry to know the clinical trial did not work for you.

Last week I had a conversion with my Onc. In his opinion, Roche's immunotherapy for mCRC is a good candidate for a clinical trial. Please see Roche's Investor Update dated May 18, 2017.
It states that if RO6958688 is combined with atezolizumab, the disease control is 82%:
18% partial response
64% stable disease
https://www.roche.com/investors/updates ... -05-18.htm

Currently Roche have phase 1 trials for there medicine in the US:
https://clinicaltrials.gov/ct2/show/NCT ... =ab&rank=1

That's a fascinating approach. If I'm reading it correctly, it creates a bridge-molecule between T-Cells and the cell surface if CEA is highly expressed (the same CEA in the blood tests that we get).

I hope you get a new plan B trial very soon. I am sorry the last one didn’t help

NHMike wrote:

KElizabeth wrote:

NHMike wrote:Do you know your KRAS mutation?

Yes. I have KRAS mutation as well as TP53 and APC.

I think that you're the first person that I've run into here with multiple mutations and these are in multiple genes as well.

TP53 and APC are supposed to regulate cell growth and prevent tumors.

I hope that your doctors can come up with something.

I was not aware that there was any rarity in tp53 or APC. I thought they were all common mutations.

NHMike wrote:

boswind wrote:Hi KElizabeth,

Sorry to know the clinical trial did not work for you.

Last week I had a conversion with my Onc. In his opinion, Roche's immunotherapy for mCRC is a good candidate for a clinical trial. Please see Roche's Investor Update dated May 18, 2017.
It states that if RO6958688 is combined with atezolizumab, the disease control is 82%:
18% partial response
64% stable disease
https://www.roche.com/investors/updates ... -05-18.htm

Currently Roche have phase 1 trials for there medicine in the US:
https://clinicaltrials.gov/ct2/show/NCT ... =ab&rank=1

That's a fascinating approach. If I'm reading it correctly, it creates a bridge-molecule between T-Cells and the cell surface if CEA is highly expressed (the same CEA in the blood tests that we get).

Thank you. I'll check it out.

I was not aware that there was any rarity in tp53 or APC. I thought they were all common mutations.

From everything I have read you are right. TP53 and APC are common.....and almost everyone with stage 4 CRC has more than one mutation. I think there might be confusion as many standard panels only test for ones with known clinical significance (such as KRAS, BRAF) like my cancer agency. That panel came back negative for about 50 mutations. But my follow up Foundation One report revealed those in my signature.

I’m sorry to hear about your current trial. There are lots of options still out there and I hope you find the right one.

AT